Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Liver Int ; 43(9): 1984-1994, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37443448

RESUMO

BACKGROUND AND AIMS: A reduction in hepatic venous pressure gradient (HVPG) is the most accurate marker for assessing the severity of portal hypertension and the effectiveness of intervention treatments. This study aimed to evaluate the prognostic potential of blood-based proteomic biomarkers in predicting HVPG response amongst cirrhotic patients with portal hypertension due to Hepatitis C virus (HCV) and had achieved sustained virologic response (SVR). METHODS: The study comprised 59 patients from two cohorts. Patients underwent paired HVPG (pretreatment and after SVR), liver stiffness (LSM), and enhanced liver fibrosis scores (ELF) measurements, as well as proteomics-based profiling on serum samples using SomaScan® at baseline (BL) and after SVR (EOS). Machine learning with feature selection (Caret, Random Forest and RPART) methods were performed to determine the proteins capable of classifying HVPG responders. Model performance was evaluated using AUROC (pROC R package). RESULTS: Patients were stratified by a change in HVPG (EOS vs. BL) into responders (greater than 20% decline in HVPG from BL, or <10 mmHg at EOS with >10 mmHg at BL) and non-responders. LSM and ELF decreased markedly after SVR but did not correlate with HVPG response. SomaScan (SomaLogic, Inc., Boulder, CO) analysis revealed a substantial shift in the peripheral proteome composition, reflected by 82 significantly differentially abundant proteins. Twelve proteins accurately distinguished responders from non-responders, with an AUROC of .86, sensitivity of 83%, specificity of 83%, accuracy of 83%, PPV of 83%, and NPV of 83%. CONCLUSIONS: A combined non-invasive soluble protein signature was identified, capable of accurately predicting HVPG response in HCV liver cirrhosis patients after achieving SVR.


Assuntos
Hepatite C , Hipertensão Portal , Humanos , Resposta Viral Sustentada , Proteômica , Cirrose Hepática , Hipertensão Portal/tratamento farmacológico , Hipertensão Portal/etiologia , Hepacivirus , Pressão na Veia Porta , Pressão Venosa
2.
Sci Transl Med ; 10(449)2018 07 11.
Artigo em Inglês | MEDLINE | ID: mdl-29997249

RESUMO

Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune function in model organisms. The objective of this phase 2a randomized, placebo-controlled clinical trial was to determine whether low-dose mTOR inhibitor therapy enhanced immune function and decreased infection rates in 264 elderly subjects given the study drugs for 6 weeks. A low-dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor that selectively inhibits target of rapamycin complex 1 (TORC1) downstream of mTOR was safe and was associated with a significant (P = 0.001) decrease in the rate of infections reported by elderly subjects for a year after study drug initiation. In addition, we observed an up-regulation of antiviral gene expression and an improvement in the response to influenza vaccination in this treatment group. Thus, selective TORC1 inhibition has the potential to improve immune function and reduce infections in the elderly.


Assuntos
Doenças Transmissíveis/imunologia , Everolimo/uso terapêutico , Imidazóis/uso terapêutico , Imunidade , Alvo Mecanístico do Complexo 1 de Rapamicina/antagonistas & inibidores , Quinolinas/uso terapêutico , Idoso , Anticorpos Antivirais/imunologia , Doenças Transmissíveis/sangue , Doenças Transmissíveis/tratamento farmacológico , Doenças Transmissíveis/genética , Relação Dose-Resposta a Droga , Everolimo/efeitos adversos , Everolimo/farmacologia , Humanos , Imidazóis/efeitos adversos , Imidazóis/farmacologia , Influenza Humana/sangue , Influenza Humana/imunologia , Influenza Humana/prevenção & controle , Alvo Mecanístico do Complexo 1 de Rapamicina/metabolismo , Quinolinas/efeitos adversos , Quinolinas/farmacologia , Regulação para Cima/efeitos dos fármacos , Vacinação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA